NPS Pharmaceuticals, Inc. Release: New Peer-Reviewed Publication Offers Guidance for Integrating Gattex® (Teduglutide [rDNA origin]) for Injection into Management of Short Bowel Syndrome

BEDMINSTER, N.J.--(BUSINESS WIRE)--The Journal of Parenteral and Enteral Nutrition recently published clinical considerations and best-practice recommendations for introducing Gattex® (teduglutide [rDNA origin]) for injection into the management of short bowel syndrome (SBS). The recommendations conclude that integrating Gattex into a coordinated approach to treating SBS may result in more success in rehabilitating the intestine and weaning from parenteral nutrition (PN)/intravenous (IV) fluids in these patients.